{{Drugbox
| Verifiedfields = changed
| Watchedfields = changed
| verifiedrevid = changed
| IUPAC_name = (6α,11β,16α)-2-Chloro-6,9-difluoro-11,17,21-trihydroxy-16-methylpregna-1,4-diene-3,20-dione
| image2 = Halometasone cream.jpg
| width = 200
| image = Halometasone.png
| width2 = 200
<!--Clinical data-->
| tradename =  Sicorten
| Drugs.com = {{drugs.com|international|halometasone}}
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category =  
| legal_AU = <!-- Unscheduled / S2 / S3 / S4  / S8 -->
| legal_UK = <!-- GSL         / P       / POM / CD -->
| legal_US = <!-- OTC                   / Rx-only  -->
| legal_status =  
| routes_of_administration =  Topical

<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound =  
| metabolism =  
| elimination_half-life =  
| excretion =

<!--Identifiers-->
| CAS_number_Ref = {{cascite|correct|??}}
| CAS_number = 50629-82-8
| ChEMBL_Ref = {{ebicite|changed|EBI}}
| ChEMBL = 1587228
| ATC_prefix = D07
| ATC_suffix = AC12
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank =  
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = J69Z9UU41Z
|  PubChem = 9846332
|  ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}}
| ChemSpiderID = 8022046
|  smiles = O=C(CO)[C@]3(O)[C@]2(C[C@H](O)[C@]4(F)[C@@]/1(\C(=C/C(=O)C(\Cl)=C\1)[C@@H](F)C[C@H]4[C@@H]2C[C@H]3C)C)C
|  StdInChI_Ref = {{stdinchicite|changed|chemspider}}
| StdInChI = 1S/C22H27ClF2O5/c1-10-4-11-12-5-15(24)13-6-16(27)14(23)7-19(13,2)21(12,25)17(28)8-20(11,3)22(10,30)18(29)9-26/h6-7,10-12,15,17,26,28,30H,4-5,8-9H2,1-3H3/t10-,11+,12+,15+,17+,19+,20+,21+,22+/m1/s1
|  StdInChIKey_Ref = {{stdinchicite|changed|chemspider}}
| StdInChIKey = GGXMRPUKBWXVHE-MIHLVHIWSA-N

<!--Chemical data-->
| C=22 | H=27 | Cl=1 | F=2 | O=5 
| molecular_weight = 444.896 g/mol
| synonyms = <small>(6''S'',8''S'',9''R'',10''S'',11''S'',13''S'',16''R'',17''R'')-2-chloro-6,9-difluoro-11,17-dihydroxy-17-(2-hydroxy-acetyl)-10,13,16-trimethyl-6,7,8,11,12,14,15,16-octahydrocyclopenta[''a'']phenanthren-3-one</small>
}}

'''Halometasone''' is a potent (Group III) synthetic tri-halogenated [[corticosteroid]] for topical application possessing pronounced anti-inflammatory, antiexudative, antiepidermoplastic, antiallergic, and antipruritic properties. It has been approved in many European countries including Spain, Germany, Switzerland, Austria, Netherlands, Belgium, and Portugal and other countries such as China, Hong Kong, Turkey, Israel, South Africa and India.

It has been used to treat chronic [[psoriasis vulgaris]]<ref>{{cite journal |pmid=6339290 |year=1983 |last1=Galbiati |first1=G |last2=Bonfacini |first2=V |last3=Candiani |first3=F |title=Halometasone cream by day and halometasone ointment at night for the treatment of patients with chronic psoriasis vulgaris |volume=11 Suppl 1 |pages=31–3 |journal=The Journal of International Medical Research}}</ref> and non-infected acute eczematous dermatoses ([[eczema]]).<ref>{{cite journal |pmid=6339286 |year=1983 |last1=Yawalkar |first1=SJ |last2=MacArol |first2=V |last3=Montanari |first3=C |title=An overview of international clinical trials with halometasone cream |volume=11 Suppl 1 |pages=1–7 |journal=The Journal of International Medical Research}}</ref> One study demonstrated that 0.05% halometasone cream was more effective than 0.05% [[betamethasone]] cream in treating dermatitis, though both were well-tolerated with no systemic adverse effects reported.<ref>{{cite journal |pmid=6342285 |year=1983 |last1=Schuppli |first1=R |last2=Dressler |first2=H |last3=Yawalkar |first3=SJ |last4=Weirich |first4=EG |title=Comparative clinical trial of a new trihalogenated dermatocorticoid (halometasone) versus betamethasone dipropionate |volume=58 |issue=4 |pages=230–7 |journal=Zeitschrift für Hautkrankheiten}}</ref>

==References==
{{Reflist|2}}

{{Glucocorticoids}}
{{Glucocorticoidics}}

[[Category:Corticosteroids]]
[[Category:Organochlorides]]
[[Category:Organofluorides]]